Literature DB >> 13678420

Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage.

Suzanne L Jacques1, Athan Kuliopulos.   

Abstract

Thrombin activation of human platelets is mediated by the high-affinity PAR1 (protease-activated receptor-1) and the low-affinity PAR4 receptor. PAR1 and PAR4 exhibit markedly disparate kinetics of activation that likely reflect differences in the macromolecular association of thrombin with their respective N-terminal extracellular domains (exodomains). Here we examine the mechanism of initial thrombin binding and cleavage of the high- and low-affinity PAR exodomains using steady-state kinetic analyses. We showed that the PAR4 exodomain lacks the functional hirudin-like sequence found in PAR1 and does not bind exosite I to cause allosteric activation or inhibition of thrombin. Instead, PAR4 contains an anionic cluster, Asp(57)...Asp(59) ...Glu(62)...Asp(65) (DDED), in its exodomain, which slows the dissociation of PAR4 from the cationic thrombin. The analogous anionic residues in the PAR1 exodomain do not influence affinity for thrombin. Although PAR4 is cleaved more slowly than PAR1 on the cell surface, peptides containing the PAR4 P(4)-P(1) active-site-interacting sequence, Pro(45)-Ala-Pro-Arg (PAPR), are efficiently cleaved due to the optimal placement of dual prolines at positions P(4) and P(2). In comparison, thrombin has low affinity and slow cleavage rates for peptides that have a P(3) proline as occurs in human PAR3. Thus, to compensate for the lack of exosite I binding, PAR4 utilizes proline residues in its P(4)-P(1) sequence to provide high-affinity interactions with the active site and an anionic cluster to slow dissociation from the cationic thrombin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13678420      PMCID: PMC1223816          DOI: 10.1042/BJ20030954

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  32 in total

1.  Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin.

Authors:  M J Shapiro; E J Weiss; T R Faruqi; S R Coughlin
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

2.  Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin.

Authors:  B J Backes; J L Harris; F Leonetti; C S Craik; J A Ellman
Journal:  Nat Biotechnol       Date:  2000-02       Impact factor: 54.908

3.  Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets.

Authors:  L Covic; A L Gresser; A Kuliopulos
Journal:  Biochemistry       Date:  2000-05-09       Impact factor: 3.162

4.  Evidence for multiple enzyme site involvement in the modulation of thrombin activity by products of prothrombin proteolysis.

Authors:  F Shi; P J Hogg; D J Winzor; C M Jackson
Journal:  Biophys Chem       Date:  1998-12-14       Impact factor: 2.352

5.  Exosite binding tethers the macromolecular substrate to the prothrombinase complex and directs cleavage at two spatially distinct sites.

Authors:  D S Boskovic; S Krishnaswamy
Journal:  J Biol Chem       Date:  2000-12-08       Impact factor: 5.157

6.  Exosite interactions determine the affinity of factor X for the extrinsic Xase complex.

Authors:  R J Baugh; C D Dickinson; W Ruf; S Krishnaswamy
Journal:  J Biol Chem       Date:  2000-09-15       Impact factor: 5.157

7.  Role of regulatory exosite I in binding of thrombin to human factor V, factor Va, factor Va subunits, and activation fragments.

Authors:  K R Dharmawardana; S T Olson; P E Bock
Journal:  J Biol Chem       Date:  1999-06-25       Impact factor: 5.157

8.  Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains.

Authors:  S W Hall; M Nagashima; L Zhao; J Morser; L L Leung
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

9.  Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries.

Authors:  J L Harris; B J Backes; F Leonetti; S Mahrus; J A Ellman; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

10.  PAR3 is a cofactor for PAR4 activation by thrombin.

Authors:  M Nakanishi-Matsui; Y W Zheng; D J Sulciner; E J Weiss; M J Ludeman; S R Coughlin
Journal:  Nature       Date:  2000-04-06       Impact factor: 49.962

View more
  33 in total

1.  A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant.

Authors:  Shauna L French; Claudia Thalmann; Paul F Bray; Lynn E Macdonald; Andrew J Murphy; Mark W Sleeman; Justin R Hamilton
Journal:  Blood Adv       Date:  2018-06-12

2.  Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.

Authors:  Rajashree Rana; Tianfang Huang; Georgios Koukos; Elizabeth K Fletcher; Susan E Turner; Andrew Shearer; Paul A Gurbel; Jeffrey J Rade; Carey D Kimmelstiel; Kevin P Bliden; Lidija Covic; Athan Kuliopulos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-04-05       Impact factor: 8.311

3.  Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.

Authors:  Ruchika Sharma; Amanda P Waller; Shipra Agrawal; Katelyn J Wolfgang; Hiep Luu; Khurrum Shahzad; Berend Isermann; William E Smoyer; Marvin T Nieman; Bryce A Kerlin
Journal:  J Am Soc Nephrol       Date:  2017-04-19       Impact factor: 10.121

4.  Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia.

Authors:  Leila M Sevigny; Karyn M Austin; Ping Zhang; Shogo Kasuda; Georgios Koukos; Sheida Sharifi; Lidija Covic; Athan Kuliopulos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-09-22       Impact factor: 8.311

Review 5.  Protease-activated receptors in hemostasis.

Authors:  Marvin T Nieman
Journal:  Blood       Date:  2016-04-28       Impact factor: 22.113

6.  PAR4 (Protease-Activated Receptor 4): PARticularly Important 4 Antiplatelet Therapy.

Authors:  Xu Han; Marvin T Nieman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-02       Impact factor: 8.311

Review 7.  The domino effect triggered by the tethered ligand of the protease activated receptors.

Authors:  Xu Han; Marvin T Nieman
Journal:  Thromb Res       Date:  2020-08-04       Impact factor: 3.944

8.  Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel.

Authors:  Carey Kimmelstiel; Ryan Stevenson; Nga Nguyen; Layla Van Doren; Ping Zhang; James Perkins; Navin K Kapur; Andrew Weintraub; Vilma Castaneda; Athan Kuliopulos; Lidija Covic
Journal:  Thromb Res       Date:  2019-02-13       Impact factor: 3.944

9.  Development and characterization of monoclonal antibodies against Protease Activated Receptor 4 (PAR4).

Authors:  Michele M Mumaw; Maria de la Fuente; Amal Arachiche; James K Wahl; Marvin T Nieman
Journal:  Thromb Res       Date:  2015-04-09       Impact factor: 3.944

Review 10.  Platelet thrombin receptor antagonism and atherothrombosis.

Authors:  Dominick J Angiolillo; Davide Capodanno; Shinya Goto
Journal:  Eur Heart J       Date:  2009-11-30       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.